Most common type of skin cancer
POPULARITY
4 episodes with basal cell carcinoma
3 episodes with basal cell carcinoma
2 episodes with basal cell carcinoma
3 episodes with basal cell carcinoma
2 episodes with basal cell carcinoma
2 episodes with basal cell carcinoma
4 episodes with basal cell carcinoma
2 episodes with basal cell carcinoma
2 episodes with basal cell carcinoma
In this episode, we review the high-yield topic of Basal Cell Carcinoma of the Skin from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode of the GeriPal podcast, we dive into the fascinating world of geriatric dermatology, or "GeriDerm," with two exceptional guests: Dr. Daniel Butler from the University of Arizona and Dr. Eleni Linos from Stanford University. First, we tackle the big question: how do we keep our skin healthy as we age? I see this on a daily basis with my own skin, but I'm unsure what to do about it, including whether we all need to use sun protection and moisturizers, and if so, which ones? Then we explore the lag time to benefit in dermatology by examining whether we need to treat every actinic keratosis and basal cell carcinoma aggressively, or whether there are cases where we can opt for watchful waiting. We also explore chronic itch with Daniel, covering the three main sources of itch and how our management should change accordingly. Importantly, antihistamines were not a prominent part! We finally asked Eleni whether artificial intelligence (AI) and digital tools can revolutionize the way we diagnose and manage skin conditions, especially in older adults. For a deeper dive into the topic, check out these two papers that we talk about on the podcast Daniel's JAMA paper on Chronic Pruritus Elani's JAMA IM paper on Active Surveillance as a Management Option for Low-risk Basal Cell Carcinoma
This DermSurgery Digest bonus content aptly named “At the Microscope” shares the latest research and techniques in dermatopathology. In this episode, contributors review Histologic Changes Observed in Basal Cell Carcinomas. Contributors to this podcast include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Ashley Elsensohn, MD, MPH, DermSurgery Digest at the Microscope co-host; Christine Ahn, MD; Jeff Gardner, MD; Marina K. Ibraheim, MD; and Michael P. Lee, MD.Articles featured in this episode include: “Squamous Change in Basal-Cell Carcinoma with Drug Resistance” The New England Journal of Medicine “Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases” The American Journal of Dermatopahology“Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation” Journal of The European Academy of Dermatology & Venereology“Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib” Journal of Drugs in DermatologyYour feedback is encouraged. Please contact communicationstaff@asds.net.
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Dr. Fiorinda Muhaj discusses advanced BCC, and systemic therapy options for treatment.
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to provide additional details from the company's Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of Basal Cell Carcinoma. The data showed the strongest treatment response in the 200-microgram cohort, which achieved 73% clinical clearance and 40% histological clearance at Day 57. The results highlight the therapeutic potential of the company's SkinJect platform, which uses microneedle technology to deliver chemotherapy directly into skin lesions without surgery. According to Medicus Pharma, the findings are particularly notable given the device-based mechanism of SkinJect. The microneedle delivery process itself may produce biological activity, which can contribute to responses even in the placebo arm of the trial. In this study, the placebo microneedle array (P-MNA) was not tip-loaded with the chemotherapeutic agent but could still stimulate a biological response due to the mechanical action of the device. The company noted that active placebo arms are not uncommon in device-drug combination trials and can be considered an acceptable regulatory data point. Importantly, the results demonstrated a clear separation in treatment response between the D-MNA therapy arm and the placebo microneedle arm in the 200-µg cohort, with clinical clearance rates of 73% and 38% respectively. Management believes the dataset represents decision-grade evidence supporting the continued advancement of the SkinJect program as a potential non-surgical treatment option for patients with basal cell carcinoma. The company plans to move forward with an End-of-Phase-2 meeting with the U.S. Food and Drug Administration to determine the optimal registrational development pathway and explore. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #RazaBokhari #Biotech #ClinicalTrials #Phase2Trial #BasalCellCarcinoma #SkinCancer #Doxorubicin #MicroneedleArray #DrugDelivery #FDA #BiotechInnovation #MedicalResearch #CancerTreatment #HealthcareInnovation #Biopharma #SkinJect #Biotech
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Dr. Fiorinda Muhaj discusses the management of high-risk BCC.
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Dr. Fiorinda Muhaj discusses the management of low-risk BCC.
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Dr. Fiorinda Muhaj discusses the risk factors for developing BCC, and how it is diagnosed.
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Dr. Fiorinda Muhaj discusses how patients with BCC can follow up after treatment, and how to help prevent future BCC occurrences.
Does having darker skin really protect you from skin cancer? Can you imagine getting a Pap smear every single day for 21 years just to help your husband’s research? And, what do you do if your vagina involuntarily “clenches” during sex. In this episode, we speak to Professor Georgina Long, Medical Director of Melanoma Institute Australia (MIA) and 2024 Australian of the Year, to decode Australia’s complicated relationship with the sun. We talk about the "ABCDE" rule for checking your moles, whether darker skin tones are at less risk of melanoma and why you should be taking photos of your skin spots.Plus, in Med School, Claire and Dr Mariam pay tribute to the unsung heroines of medical history - from the wife of Dr. Papanicolaou (who underwent daily pap smears for 21 years ) to Anarcha Westcott, the enslaved woman known as the 'mother of modern gynecology', who endured 30 experimental surgeries without anaesthesia.And, in our Quick Consult, Dr Mariam helps a listener named Sarah who is struggling with Vaginismus. We break down exactly what this condition is, why it is a physical reflex rather than "just in your head" and the multidisciplinary team you need to help reclaim your sex life.THE END BITS All your health information is in the Well Hub. If you've been putting off a skin check, this is your sign to book it. For more information on sun safety, visit the Cancer Council. We understand that conversations about cancer can be difficult, whether you're navigating your own diagnosis, supporting a loved one, or remembering someone you've lost. If today's episode has brought up difficult feelings, please reach out. The Cancer Council offers a confidential support line staffed by specialist nurses, and you can call them on 13 11 20. For more specific information on the topics we discussed today, organisations like the Cancer Council, the Australian Skin Cancer Foundation, and the Melanoma & Skin Cancer Advocacy Network (MSCAN) provide dedicated advocacy, education and community support for patients impacted by all forms of skin cancer. And if you just need to talk to someone immediately, you can always call Lifeline on 13 11 14. Remember to be kind to yourself, and please don't hesitate to seek support. GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Hosts: Claire Murphy and Dr Mariam Guest: Professor Georgina Long Senior Producers: Claire Murphy and Sally Best Audio Producer: Scott Stronach Video Producer: Julian Rosario Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional. +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.
Thanksgiving and overindulgenceA food poisoning incidentObservations on health at ThanksgivingWhat do you think of online sites offering prescriptions for hair loss via a questionnaire?
My granddaughter suffers from menstrual cramps. Do you have any suggestions?Do you recommend nicotinamide daily to prevent recurrence of basal cell cancers?What works best to lower fibrinogen?I've been on Ozempic for a year and have diarrhea every morning!Is bypass surgery still being done?Would you recommend Bergamot for fatty liver?
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received encouraging feedback from its recent Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development pathway of its innovative microneedle-based therapy, Skinject™ (D-MNA), for the treatment of basal cell carcinoma (BCC). The Type C meeting focused on reviewing key elements of the protocol, including study design, endpoints, and patient population definitions for upcoming clinical trials. According to Dr. Bokhari, the FDA provided clarity and alignment on several critical points. Specifically, the agency indicated that a relative bioavailability study with D-MNA, administered under certain conditions, could serve as a basis for establishing a regulatory bridge while addressing bioavailability requirements for the product. Importantly, the FDA offered constructive and supportive guidance on multiple aspects of the proposed development program, including the appropriate primary endpoint for the next clinical study. The company must define the patient population, such as tumor size limits, lesion location restrictions, and histological confirmation requirements and design a randomized, double-blind, placebo-controlled trial to demonstrate efficacy in treating BCC. This regulatory clarity is expected to further strengthen Medicus Pharma's ongoing clinical program. The company is currently conducting its Phase 2 trial across nine clinical sites in the United States. Patient randomization began in August 2024. In March 2025, Medicus Pharma announced results from an interim analysis of the Phase 2 study, showing a positively trending clinical clearance rate exceeding 60%. The interim data, based on more than half of the targeted 60 patients randomized at the time, were highly encouraging, although final results may vary once the study is fully completed. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation
What’s Your Wrinkle®, the plastic surgery show with Dr. Arthur Perry
My daughter Meredith Perry joins me as cohost for this show. Meredith is CEO of Elemind Technologies, maker of a wearable device that helps you sleep. On today's show, we discuss her technology and we discuss how a plastic surgeon removes skin cancers and reconstructs wounds to make you look as good as possible.
Do you recommend systemic therapy for patients with advanced basal cell carcinoma (BCC)? Credit available for this activity expires: 4/1/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/community-focus-addressing-gaps-and-elevating-care-patients-2025a10007j7?ecd=bdc_podcast_libsyn_mscpedu
Send us a text
Interview with Babette J. A. Verkouteren, MD, PhD, author of Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. Hosted by Adewole S. Adamson, MD. Related Content: Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma
JAMA Dermatology Author Interviews: Covering research on the skin, its diseases, and their treatment
Interview with Babette J. A. Verkouteren, MD, PhD, author of Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. Hosted by Adewole S. Adamson, MD. Related Content: Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness. Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon." "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Download the transcript here
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness. Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon." "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Listen to the podcast here
In episode 140 of the Glow Journal podcast, host Gemma Dimond talks to the founder of Airyday, Frances van der Velden. I knew this was going to be a great storytelling episode, because I was already reasonably versed in the Airyday backstory, but what blew me away in this conversation was how much actual tangible business advice Frances so openly shared. Frances was diagnosed with a Basal Cell Carcinoma, which led to her trying more or less every sunscreen on the market to find a formula she loved and would be happy to wear every day. When she couldn't find one that ticked every box, she set to work on developing Airyday- an SPF wardrobe that launched in 2022 with four sunscreens. Beauty retail giant Sephora reached out to Frances a mere six weeks post-launch, and today, two years in, Airyday is stocked in Sephora stores nationally and through a whopping 600 clinic stockists. Frances explains that this was largely thanks to a high risk ad spend strategy that she explains far better than I can. In this conversation, Frances shares the realities of such major growth in such a short timeframe, how her marketing investment allowed Airyday to cut through the noise in a saturated market, and her advice on getting your brand seen by the decision makers at the country's biggest retailers. Read more at glowjournal.comFollow Airyday on Instagram @airyday.officialStay up to date with Gemma on Instagram at @gemdimond and @glow.journal, or get in touch at hello@gemkwatts.com Hosted on Acast. See acast.com/privacy for more information.
Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemic approach to treatment; Review the clinical implications of the evidence on approved and emerging systemic therapies in patients with advanced BCC; and Describe practical strategies to optimize systemic treatment over the long term for patients with advanced BCC. This activity is intended for US healthcare professionals only.
In this episode, we review the high-yield topic of Basal Cell Carcinoma from the Nutrition section at Medbullets.com Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.
Roswell Park's Dr. Kim Brady on basal cell carcinoma, which Gov. Hochul announced Thursday she'll get treatment for full 281 Thu, 12 Sep 2024 18:49:13 +0000 J7wHEputg7727exfiiHCZupdLsKFtHUQ news & politics,news WBEN Extras news & politics,news Roswell Park's Dr. Kim Brady on basal cell carcinoma, which Gov. Hochul announced Thursday she'll get treatment for Archive of various reports and news events 2024 © 2021 Audacy, Inc.
To have your question featured in a future video, please email: questions@drmdc.health
The saying "saving your skin" takes on extra meaning when you are outdoors. Living a "sun and fun" lifestyle can come with a price -- the sun's damaging UV rays and the risk of skin cancer. Hopefully, you practice safety by using sunscreens, hats and clothing to mitigate those harmful rays. Some people forget that sun damage and skin cancer can be synonymous. As spring and summer approach, how do we avoid skin cancer? And if it leaves a concerning spot on the skin, what do we do next? Host: Jonathan Fialkow, M.D., Chief Medical Officer at Baptist Health who oversees Population Health, Primary Care, Cardiology, Endocrinology and other Medical Specialties Guest: Michael Raish, M.D., Mohs Micrographic Surgeon and Dermatologist, Baptist Health Miami Cancer Institute
About The Guest(s): - Dr. Robi N. Maamari: Facial plastic surgeon on faculty at Washington University and the School of Medicine in St. Louis. - Dr. Chau Pham: Assistant professor of Ophthalmology and Visual Sciences at the University of Iowa. - Dr. John Holtz: Private practice Oculofacial plastic surgeon at Ophthalmologic Plastic and Cosmetic Surgery in St. Louis. Episode Notes: Dr. Robi N. Maamari hosts a journal club podcast where he discusses articles from the July and August issue of Ophthalmic Plastic and Reconstructive Surgery (OPRS). In this episode, he reviews three articles regarding, Recurrence and Surveillance Strategies for Orbital Basal Cell Carcinoma with Dr. Chau Pham and Dr. John Holtz. Key Takeaways: - Absorbable and non-absorbable sutures have similar outcomes in conjunctival Müllerectomy with or without tarsectomy. - Globe-sparing excisions for basal cell carcinoma with anterior orbital invasion can lead to visual morbidity and recurrence. - Regular surveillance with MRI scans is crucial for detecting recurrence in patients with orbital basal cell carcinoma. - Understanding and recognizing artifacts on MRI scans is essential to avoid misdiagnosis and unnecessary procedures. If you're an ASOPRS Member, Surgeon or Trainee and are interesting in hosting a podcast episode, please submit your idea by visiting: asoprs.memberclicks.net/podcast
Confessing our faults to one another is an important responsibility of good church membership
Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, and Dr Anna Pavlick from the Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss available and novel treatment strategies for cutaneous squamous cell carcinoma and basal cell carcinoma. CME information and select publications here (https://researchtopractice.com/InsidetheIssue2023/NonmelanomaSkin)
Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson, including the following topics: Introduction: Immunology of Melanoma (0:00) Melanoma (8:26) Cutaneous Squamous Cell Carcinoma (43:15) Basal Cell Carcinoma and Merkel Cell Carcinoma (52:55) CME information and select publications
Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.
Vidcast: https://www.instagram.com/p/CrKi3amvErV/ Dr. Smith speaks with a WBZ Radio caller about the management of her basal cell cancer. https://my.clevelandclinic.org/health/diseases/4581-basal-cell-carcinoma #basalcellcarcinoma #skincancer #mohs #efudex #5fu
Please visit answersincme.com/BRY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses current and emerging strategies to optimize the multidisciplinary care of advanced basal cell carcinoma (BCC) with immunotherapy.Upon completion of this activity, participants should be better able to: Identify patients with BCC for whom a second-line immunotherapy regimen would be appropriate; Review the clinical profiles of immunotherapy-based regimens for the second-line treatment of advanced BCC; and Outline multidisciplinary strategies to optimize the long-term care of patients with advanced BCC who are on an immunotherapeutic approach.
In this episode, we review the high-yield topic of Basal Cell Carcinoma of the Skin from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message
Please visit answersincme.com/WZE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies for optimizing immunotherapy in advanced basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Identify patients with advanced BCC who may benefit from immunotherapy; Review the clinical impact of available and emerging immunotherapies for the management of patients with advanced BCC; and Describe practical strategies to manage and monitor patients with advanced BCC on immunotherapy over both the long and short term.
David E. Miller, MD interviewed by Harrison P. Nguyen, MBA, MPH
It's a diagnosis nobody wants to hear: "You've got cancer." Join Premier dermatologists as they explain the process of treating (and hopefully curing) a skin cancer.
In this podcast, Dr. Riddell Scott, a dermatologist with Ridgeview Medical Center and Clinics, leads the discussion about skin cancer. Dr. Scott discusses changes to our DNA, what dermatology office visits look like, types of skin cancer and treatments available, as well as prevention efforts. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Explain the 3 main types of skin cancer and how they differ from each type. State how most skin cancers are treated. Identify how sun exposure contributes to the onset of skin cancer. Describe 3 activities that help to reduce skin cancer incidence. Counsel patients about skin cancer prevention efforts. CME credit is only offered to Ridgeview Providers & Allied Health Staff for this podcast activity. Complete and submit the online evaluation form, after viewing the activity. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at rmccredentialing@ridgeviewmedical.org. To receive continuing education credit for this activity - click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.) DISCLOSURE ANNOUNCEMENT The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics. Any re-reproduction of any of the materials presented would be infringement of copyright laws. It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES: *See the attachment for additional show information. What happens to our DNA- Ultraviolet light hits skin and energy is transferred- Melanocytes & Melanin - Skin cancer risk factors Office visits- Family history - Dermatology: pattern recognition - Dermatoscope - Patient education - Repeat exams & recommendations - ABCDE (asymmatry, border irregularity, color variation, diameter, evolution) Types of skin cancer: Squamous , Basal Cell Carcinoma, Melanoma- Cell physiology - Metastatic rate - Presentation - Primary vs secondary sources - Diagnosis - Stages (0,1,2) - Treatment (biopsy, MOHS, surgery, radiation, medication) Skin Cancer Prevention:- 3 Big Things: - Wear a wide brimmed hat - Wear sun protective clothing - Wear sun screen daily - Sunscreen recommendations * For more information - see attached "Show Notes". Thanks for listening.
Vishal Patel, MD, FAAD and Anthony Rossi, MD, FAAD interviewed by Brad Glick, DO, MPH, FAAD
Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long, MD (@long_brit), we look at two posts: recognizing skin cancer and new onset hyperglycemia. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play
Scott Dinehart, MD interviewed by Steven Chen, MD, MPH, FAAD
This week's episode covers everything you need to know about basal cell carcinoma including- presentation- risk factors- histological subtypes- poor prognostic factors- management including topical treatments, surgery, radiotherapy and targeted treatmentsDisclaimerThe information in this podcast is intended as a revision aid for the purposes of the General Surgery Fellowship Exam.This information is not to be considered to include any recommendations or medical advice by the author or publisher or any other person. The listener should conduct and rely upon their own independent analysis of the information in this document.The author provides no guarantees or assurances in relation to any connection between the content of this podcast and the general surgical fellowship exam. No responsibility or liability is accepted by the author in relation to the performance of any person in the exam. This podcast is not a substitute for candidates undertaking their own preparations for the exam.To the maximum extent permitted by law, no responsibility or liability is accepted by the author or publisher or any other person as to the adequacy, accuracy, correctness, completeness or reasonableness of this information, including any statements or information provided by third parties and reproduced or referred to in this document. To the maximum extent permitted by law, no responsibility for any errors in or omissions from this document, whether arising out of negligence or otherwise, is accepted.The information contained in this podcast has not been independently verified.© Amanda Nikolic 2022
Christi is getting personal this week as she shares an unexpected life update. Buy your 2022 Begin Planner: https://www.christilukasiak.com/begin Follow Christi on Instagram: https://www.instagram.com/christilukasiak Check out Christi's TikTok: https://www.tiktok.com/@christilukasiak Watch Christi's latest YouTube video: https://www.youtube.com/christilukasiak Go to https://greenchef.com/couch130 & use code: couch130 to get $130 off, plus free shipping! More podcasts at WAVE: https://podcasts.apple.com/us/artist/wave-podcast-network/1437831426
CancerNetwork® spoke with Emily Smith, MD, of the Ellis Fishchel Cancer Center, University of Missouri, about a patient case published in the December issue of the journal ONCOLOGY titled, “Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma.” Smith and colleagues detailed a case regarding a 56-year-old man who the team of care providers diagnosed with metastatic basal cell carcinoma arising from a carcinosarcoma. In the conversation, Smith talked about what makes this patient case unique, the timeline of this specific patient's disease and treatment, the rarity of basal cell carcinoma arising from a carcinosarcoma, and plenty more. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
In this episode, we review the high-yield topic of Basal Cell Carcinoma from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for patients with locally advanced or metastatic basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor (or an HHI) is not appropriate
Dr. Bobby Awadalla is a well-respected board-certified dermatologist and Mohs micrographic surgeon. He brings his extensive knowledge of dermatology and state-of-the-art expertise in skin cancer removal, facial plastic reconstruction and cosmetic dermatology to his role as the creator and entrepreneur behind UVO. An outdoor enthusiast himself, Dr. Awadalla enjoys swimming, body surfing, running, basketball and travel. For years, he heard all the reasons why people avoid topicals – they don't like the smell, the feel, the burning in their eyes or the hassle of applying. Because he knows the importance of a good skin care regimen, Dr. Awadalla spent years researching natural ways to support skin health from the inside out, which led him to develop UVO.UVO is a drinkable multivitamin formulated specifically by Dr. Bobby Awadalla, to give your skin the nutrients it needs to function optimally. UVO contains over 20 vitamins, antioxidants, and nutrients from superfoods that help promote anti-aging, restore beauty, and support overall skin health from the inside-out. In addition to being a powerful daily multivitamin, UVO is also non-GMO, vegan, gluten-free, and does not contain any artificial flavors or preservatives. For more information, please visit drinkuvo.com.
© 2020-2026 Ivy Podcast Discovery LLC
